share_log

Biodexa Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Feb 24 02:30
Summary by Futu AI
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, announced positive top-line results from its Phase I clinical trial for MTX110 in treating diffuse midline glioma (DMG). The trial, conducted by Columbia University Irving Medical Center, showed a median overall survival of 16.5 months compared to 10.0 months in a comparable cohort. Despite not being powered for efficacy, the results were favorable and will be presented at the International Symposium on Pediatric Neuro-Oncology in July 2024. The study also reported a severe adverse event in one patient, deemed unrelated to the study drug. Additionally, Biodexa provided an update on tolimidone, a potential treatment for Type 1 diabetes. An in vitro experiment conducted by a CRO did not yield conclusive results, but the company plans to proceed with an in vivo preclinical study and a Phase IIa study later in the year. Biodexa's R&D update was included in their Form 6-K filing with the SEC for February 2024, and the press release was dated February 23, 2024.
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, announced positive top-line results from its Phase I clinical trial for MTX110 in treating diffuse midline glioma (DMG). The trial, conducted by Columbia University Irving Medical Center, showed a median overall survival of 16.5 months compared to 10.0 months in a comparable cohort. Despite not being powered for efficacy, the results were favorable and will be presented at the International Symposium on Pediatric Neuro-Oncology in July 2024. The study also reported a severe adverse event in one patient, deemed unrelated to the study drug. Additionally, Biodexa provided an update on tolimidone, a potential treatment for Type 1 diabetes. An in vitro experiment conducted by a CRO did not yield conclusive results, but the company plans to proceed with an in vivo preclinical study and a Phase IIa study later in the year. Biodexa's R&D update was included in their Form 6-K filing with the SEC for February 2024, and the press release was dated February 23, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.